Cisbio International Announces Launch of HTRF® KinEASE™ TK at SBS

Date Posted: Tuesday, April 17, 2007

Print Email to a friend

Cisbio international has announced the launch of HTRF® KinEASE™ TK at the SBS Conference in Montreal, Canada.

HTRF® KinEASE™ TK is a universal assay for high throughput screening of Tyrosine (Tyr) kinases, major targets in drug discovery, in particular in oncology research.

With the development of this tool, Cisbio now offers its customers the ability to use a reliable kinase screening platform based on one technology to address a broad range of kinase targets.

HTRF® KinEASE™ TK combines a peptide substrate called S4 and a single monoclonal antibody with Cisbio’s HTRF® (homogeneous time resolved fluorescence) technology, a technology for the detection of molecular interactions of proteins in vitro.

HTRF® KinEASE™ TK limits assay development time and is miniaturizable and flexible, meaning the assay can be performed under a wide range of kinase assay conditions, for instance with low consumption of enzyme or with any ATP concentration.

HTRF® KinEASE™ TK is the fifth kit in the HTRF® KinEASE™ platform, developed in collaboration with Millipore (Upstate) for profiling and HTS of Serine/Threonine (Ser/Thr) kinases.

Launched in March 2006, the platform consists of four kits combining 3 biotinylated substrates, S1, S2 and S3, with a monoclonal antibody and HTRF®. Since this new Tyr kinase assay is based on the same monoclonal antibody principle as HTRF® KinEASE™, the implementation of the assay by Cisbio’s existing HTRF® KinEASE™ customers is very straightforward.

Further Information: http://www.htrf.com

Request Information From Vendor



Related Products

Cisbio International Launches HTRF® Cell-Based Assays at SBS
Company expands integration of d2 acceptor molecule to assays in inflammation and metabolic diseases fields.

Cisbio international Expands List of Serine/Threonine Kinases Validated using HTRF® KinEASE™
Company’s universal kinase assay platform now validated on 104 kinases

Cisbio Introduces IP-One ELISA at 4th Annual GPCR Congress
Company’s second IP-One assay can be used by laboratories focused on GPCR-based targets.



Related news from our archive

Cisbio Awarded $1.9 M Research Grant By France’s National Research Agency
Company’s intracellular molecular imaging project selected from 400 grant applications highlights R&D; initiatives.